A Study of Robot-Assisted Bronchoscopy in Chinese Participants With Lung Lesions
- Conditions
- Lung Neoplasms
- Interventions
- Device: Robot-assisted Bronchoscopy (Monarch Platform)
- Registration Number
- NCT05426213
- Lead Sponsor
- Auris Health, Inc.
- Brief Summary
Robot-assisted bronchoscopy biopsy procedure will be conducted for all eligible subjects under general anesthesia status by trained investigators in hospital.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Capable and willing to give informed consent
- Acceptable candidate for an elective, non-emergency bronchoscopic procedure
- Lung lesions suspected of malignancy, between 8-50 millimeters (mm) in diameter size identified on thin slice (0.9-1.25 mm) computed tomography (CT) scan within 14 days, requiring bronchoscopic biopsy for diagnosis
- No more than 1 lung lesion will be targeted for robot-assisted bronchoscopy biopsy
Pre-Operative
- Participants with pure ground-glass opacity lesions on pre-procedure chest CT
- Participants with the target lesion having endobronchial involvement seen on chest CT
- Medical contraindications to bronchoscopy and/or anesthesia as assessed by the investigator (such as severe cardiac arrhythmias, severe hypertension, severe cardiopulmonary dysfunction, myocardial infarction, unstable angina pectoris et cetera [etc]) precluding safe bronchoscopic procedure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Robot-assisted Bronchoscopy Robot-assisted Bronchoscopy (Monarch Platform) Participants with 8-50 millimeters (mm) diameter size lung lesions identified on computed tomography (CT) scan will be enrolled for robotic assisted bronchoscopy (Monarch Platform) biopsy procedure.
- Primary Outcome Measures
Name Time Method Navigation Success Rate Intraoperative Navigation success rate is defined as the percentage of successful navigation to the targeted lung lesion (lesion localization) as confirmed by radial probe endobronchial ultrasound (R-EBUS) imaging through Monarch Platform during bronchoscopy procedure.
- Secondary Outcome Measures
Name Time Method Total Procedure Time Intraoperative Total procedure time is defined by the time the robotic bronchoscope is inserted into the oropharynx until the robotic bronchoscope is removed.
Number of Conversion to Conventional Bronchoscopic Procedure Intraoperative Number of conversion to conventional bronchoscopic procedure is defined as the number of procedures converted to other diagnostic modality due to inability of the Monarch platform to complete the intended bronchoscopy.
Time to R-EBUS Confirmation Intraoperative Time to R-EBUS confirmation is defined by the time from the robotic bronchoscope inserted into the oropharynx to the localization of the targeted lesion confirmed by R-EBUS.
Time to the Tissue Acquisition Intraoperative Time to the tissue acquisition is defined by the time the robotic bronchoscope is inserted into the oropharynx until the tissue acquisition is confirmed by the Rapid On-site evaluation (ROSE).
Number of Participants with Pneumothorax Requiring Intervention Up to 7 days post procedure Number of participants with pneumothorax requiring intervention (rated as greater than \[\>\] Grade 1 according to the Common Terminology Criteria for Adverse Events \[CTCAE\] scale) will be reported.
Number of Participants with Device or Procedure Related Respiratory Failure Up to 7 days post procedure Number of participants with device or procedure related respiratory failure (rated as \>Grade 3 according to the CTCAE scale) will be reported.
Number of Participants with Device or Procedure Related Bleeding Requiring Medical Intervention Up to 7 days post procedure Number of participants with device or procedure related bleeding requiring medical intervention (rated as \>Grade 1 according to the CTCAE scale) will be reported.
Trial Locations
- Locations (1)
Hainan General Hospital
🇨🇳Haikou, Hainan, China